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Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an
inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as
follows: patients with both an elevated C-reactive protein (410mgl
 1) and hypoalbuminaemia (o35gl
 1) were allocated a score
of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0,
respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS
and treatment received, only the GPS (HR 2.26, 95% CI 1.45–3.52, Po0.001) remained significantly associated with cancer-specific
survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent
of treatment in patients with metastatic breast cancer.
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Breast cancer is the second most common cause of cancer-related
death among women in the Western world (Cancer Stats,
www.cancerresearchuk.org; Jemal et al, 2003). Approximately,
10% of newly diagnosed breast cancer patients have locally
advanced and/or metastatic disease at the time of presentation
(Sant, 2001; Li et al, 2003). In addition, more than 40% of patients,
who are diagnosed with early-stage breast carcinoma, will
eventually experience later recurrence and/or metastatic disease
(Early Breast Cancer Trialists’ Collaborative Group, 1998).
Metastatic breast carcinoma exhibits a great deal of variability in
its clinical presentation and behaviour. The prognosis is generally
poor with a median overall survival of approximately 2–3 years
(Ali et al, 2003; Bernard-Marty et al, 2004). Current therapies are
palliative, aiming at improving or maintaining quality of life,
controlling symptoms, and prolonging survival. Nevertheless,
specific subgroups of patients exist for which, depending on the
site of metastasis and treatment given, survival may range from a
few months to several years (Nomura, 1998; Insa et al, 1999). This
prognostic uncertainty has driven the search for well-standardised
laboratory-based parameters, which have prognostic value.
Previous studies have established the prognostic importance of
the systemic inflammatory response, as evidenced by an elevated
circulating C-reactive protein concentration, in patients with
advanced solid tumours (O’Gorman et al, 2000; Mahmoud and
Rivera, 2002; Maltoni et al, 2005) including breast cancer
(Albuquerque et al, 1995; Zhang and Adachi, 1999). Recently, we
have shown that, using established cutoffs, a combination of an
elevated C-reactive protein and hypoalbuminaemia, the Glasgow
Prognostic score (GPS) has prognostic value, independent of stage
and performance status, in patients with inoperable non-small-cell
lung cancer (Forrest et al, 2003, 2004, 2005). However, there is no
information on the prognostic value of this combination in
patients with metastatic breast cancer.
The aim of the present study is to examine the relationship
between the GPS and survival in patients with metastatic breast
cancer.
PATIENTS AND METHODS
Breast cancer patients presenting, with metastatic relapse, to a
single oncology clinic in the Beatson Oncology Centre between
February 2002 and November 2004 and who had a measurement of
C-reactive protein and albumin undertaken were included in the
study. At this time no patients showed clinical evidence of
infection or other inflammatory conditions.
All patients had confirmed metastatic disease on the basis of
either clinical findings or imaging. Patients were group according
to whether they soft tissue and/or bone metastases, visceral
metastases and visceral and soft tissue and/or bone metastases.
Oestrogen receptor (ER) status was considered as positive when
nuclear staining was seen in X10% of cancer cells.
Patients who developed other malignancies, and patients with C-
reactive protein measured during a course of taxane therapy were
excluded from the study since they may produce a hypersensitivity
reaction and elevated concentrations of interleukin-6 (Tsavaris
et al, 2002; Williams et al, 2003), which is a primary mediator of
C-reactive protein (Gabay and Kushner, 1999). In total, 96 out of 295
(33%) patients with metastatic disease were eligible for the study.
The study was approved by the Research Ethics Committee of
the North Glasgow NHS Trust.
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sRoutine laboratory measurements of C-reactive protein and
albumin concentrations were carried out. The coefficient of
variation was less than 5% as established by routine quality
control procedures. The limit of detection of the assay is a
C-reactive protein concentration of less than 6mgl
 1.
The GPS was constructed as previously described (Forrest et al,
2003). Briefly, patients with both an elevated C-reactive protein
(410mgl
 1) and hypoalbuminaemia (o35gl
 1) were allocated a
score of 2. Patients in whom only one of these biochemical
abnormalities was present were allocated a score of 1. Patients in
whom neither of these abnormalities was present were allocated a
score of 0.
Statistics
Grouping of the variables was carried out using standard
thresholds. Survival (cancer-specific) analysis was performed
using the Cox proportional hazard model. Deaths up to 31st May
2005 have been included in the analysis. Multivariate survival
analysis was performed using a stepwise backward procedure to
derive a final model of the variables that had a significant
independent relationship with survival. To remove a variable from
the model, the corresponding P-value had to be greater than 0.10.
Analysis was performed using SPSS software (SPSS Inc., Chicago,
IL, USA).
RESULTS
The baseline clinicopathological characteristics of the patients with
metastatic breast cancer (n¼96) are shown in Table 1. The
majority of patients were over 50 years of age (78%), and received
active treatment (96%). C-reactive protein and albumin concen-
trations were measured prior to systemic therapy in 35 patients
and during systemic therapy in 61 patients. In all, 72 (75%)
patients had not received cytotoxic chemotherapy for metastatic
disease prior to the measurement of C-reactive protein and
albumin concentrations.
In all, 92 (96%) patients received active treatment in the form of
chemotherapy and/or endocrine therapy. In those patients in
whom Her-2 status was assessed, 14 out of 47 patients were Her-2
positive and 11 of the 14 patients received Herceptin therapy. The
majority of patients had C-reactive protein (53%) and albumin
(94%) concentrations in the normal range; the GPS was elevated in
47% of patients. Of the six patients with hypoalbuminaemia, all
had an elevated C-reactive protein concentration.
The minimum follow-up was 7 months; the median follow-up of
the survivors was 16 months. During this period 51 patients died of
their cancer. On univariate analysis, an elevated C-reactive protein
(Po0.01), hypoalbuminaemia (Po0.05), the GPS (Po0.001) and
treatment (Po0.05) were associated with poor cancer-specific
survival. On multivariate analysis of the GPS and treatment, only
the GPS (HR 2.26, 95% CI 1.45–3.52, Po0.001) remained
significantly associated with cancer-specific survival.
The relationship between clinicopathological characteristics and
an inflammation-based prognostic score (GPS) in patients with
metastatic breast cancer is shown in Table 2. The median survival
in these patients was 24 months, 13 months and 1 month for a GPS
of 0, 1 and 2, respectively (Figure 1).
DISCUSSION
In the present study, a simple inflammation-based prognostic
score (GPS) based on standard laboratory measurements of
C-reactive protein and albumin, was an independent predictor of
survival in patients with metastatic breast cancer. This work is
Table 1 Clinicopathological characteristics in patients with metastatic
breast cancer: univariate survival analysis
Patients Hazard ratio
(n¼96) (95%CI) P-value
Age (p50/450years) 21/75 0.70 (0.38–1.31) 0.266
Prior cytotoxic chemotherapies
(0/X1) 72/24 1.42 (0.76–2.65) 0.266
Metastatic site
(Nonvisceral/visceral/both) 43/14/39 1.08 (0.79–1.48) 0.625
Oestrogen receptor status
(positive/negative) 63/27 1.17 (0.65–2.12) 0.594
Disease-free interval
(42/p2 years) 67/29 1.16 (0.63–2.11) 0.633
White cell count
(p11/411 10
9l
 1) 74/3 1.13 (0.15–8.34) 0.904
Haemoglobin
(X12/o12gdl
 1) 46/30 1.75 (0.90–3.42) 0.1
C-reactive protein
(p10/410mgl
 1) 51/45 2.50 (1.40–4.48) 0.002
Albumin concentration
(X35/o35gl
 1) 90/6 3.41 (1.33–8.72) 0.011
GPS
(0/1/2) 51/39/6 2.26 (1.45–3.52) o0.001
Treatment
(Herceptin/active/supportive) 11/81/4 2.29 (1.02–5.19) 0.046
Table 2 The relationship between clinicopathological characteristics and
an inflammation-based prognostic score (GPS) in patients with metastatic
breast cancer
GPS 0
(n¼51)
GPS 1
(n¼39)
GPS 2
(n¼6) P-value
Age (p50/450years) 10/41 10/29 1/5 0.751
Prior cytotoxic
chemotherapies
(0/X1) 36/15 32/7 4/2 0.409
Metastatic site
(Nonvisceral/visceral/both) 24/9/18 16/5/18 3/0/3 0.684
Oestrogen receptor status
(positive/negative) 27/18 30/9 6/0 0.061
Disease-free interval
(42/p2 years) 35/16 27/12 5/1 0.756
White cell count
(p11/411 10
9l
 1) 40/1 28/2 6/0 0.58
Haemoglobin
(X12/o12gdl
 1) 26/14 18/12 2/4 0.334
Treatment
(Herceptin/active/supportive) 9/42/0 2/33/4 0/6/0 0.044
Survival (months) 23.8 12.7 1.2
(20.2–
27.5)
(5.1–20.3) (0.7–10.4) o0.001
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sconsistent with previous work in patients with inoperable non-
small-cell lung cancer (Forrest et al, 2003, 2004, 2005) and
improves on the prediction of survival using an elevated C-reactive
protein alone (Albuquerque et al, 1995; Zhang and Adachi, 1999).
If these results are confirmed in larger studies, the GPS may be
useful in the assessment of advanced breast cancer patients at
diagnosis and the stratification of patients entering randomised
trials.
In the present study, performance status was not recorded in the
majority of patients. However, almost all the patients received
active treatment and this would suggest that they had similar good
performance status. Moreover, performance status is subjective
(Ando et al, 2001) and the GPS has been shown to be a prognostic
factor, independent of performance status in patients with
inoperable non-small-cell lung cancer (Forrest et al, 2003, 2004).
Other recognised prognostic factors, which have been shown to
affect survival post relapse, such as ER status and disease free
interval, did not reach statistical significance. This was probably
due to the small number of patients in the present study. In
contrast, an increasing GPS, (in particular 0 vs 1) was associated
with a halving of survival. These results may point to the strength
of the systemic inflammatory response (the GPS) in predicting
survival in the patient with metastatic breast cancer.
It has been previously shown that, in patients with inoperable
non-small-cell lung cancer at diagnosis, approximately three-
quarters of patients had an abnormal GPS (1 or 2) and that these
patients had a significantly poorer outcome (Forrest et al, 2003,
2004). It was of interest that, in the present study, although the
proportion of patients with an abnormal GPS was less (47%), those
metastatic breast cancer patients with a GPS of 2 had a similarly
poorer survival. It may be that the prognostic value of the GPS is
independent of tumour type in patients with advanced cancer
(Elahi et al, 2004).
The mechanisms by which a systemic inflammatory response
(the GPS) might impact on survival in advanced cancer patients
are still not well defined. It may reflect the proinflammatory
cytokine activity, in particular interleukin-6 (McKeown et al,
2004), which not only stimulates breast tumour growth (Kur-
ebayashi, 2000), but also produce profound catabolic effects on
host metabolism (McMillan et al, 1998; Kotler, 2000). In this way,
the presence and magnitude of a chronic systemic inflammatory
response may produce progressive nutritional and functional
decline, ultimately resulting in reduced survival. Indeed, this
concept is consistent with the observation in the present study that
all patients with hypoalbuminemia had an elevated C-reactive
protein concentration.
At the time of diagnosis, there are well-established prognostic
factors on which to base the prediction of likely survival in cancer
patients. In contrast, predicting survival of patients with advanced
disease is more problematic. As a result, clinicians often over-
estimate survival (Christakis and Lamont, 2000; Glare et al, 2003).
The results of the present study suggest that the GPS may be useful
in the assessment of survival in patients with metastatic breast
cancer. It is simple to use and based on routinely available, well-
standardised measurements.
ACKNOWLEDGEMENTS
We gratefully acknowledge the assistance of Lynn Forrest.
REFERENCES
Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, Blamey RW,
Robertson JF (1995) Pre-treatment serum levels of tumour markers in
metastatic breast cancer: a prospective assessment of their role in
predicting response to therapy and survival. Eur J Surg Oncol 21:
504–509
Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y,
Sakai S (2001) Prognostic value of performance status assessed by
patients themselves, nurses, and oncologists in advanced non-small cell
lung cancer. Br J Cancer 85: 1634–1639
Ali SM, Harvey HA, Lipton A (2003) Medical management of bone
metastases; metastatic breast cancer. overview of treatment. Clin Orthop
Relat Res 415: S132–S137
Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in
systemic treatment of metastatic breast cancer. Oncologist 9: 617–632
Christakis NA, Lamont EB (2000) Extent and determinants of error in
doctors’prognoses in terminally ill patients: prospective cohort study. Br
Med J 320: 469–472
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemo-
therapy for early breast cancer: an overview of the randomised trials.
Lancet 352: 930–942
Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N (2004) Score
based on hypoalbuminemia and elevated C-reactive protein predicts
survival in patients with advanced gastrointestinal cancer. Nutr Cancer
48: 171–173
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR
(2005) A prospective longitudinal study of performance status, an
inflammation-based score (GPS) and survival in patients with inoperable
non-small-cell lung cancer. Br J Cancer 23: 1834–1836
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003)
Evaluation of cumulative prognostic scores based on the systemic
inflammatory response in patients with inoperable non-small-cell lung
cancer. Br J Cancer 89: 1028–1030
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004)
Comparison of an inflammation-based prognostic score (GPS) with
performance status (ECOG) in patients receiving platinum-based
chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer
90: 1704–1706
Gabay C, Kushner I (1999) Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med 340: 448–454
Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N
(2003) A systematic review of physicians’ survival predictions in
terminally ill cancer patients. BMJ 327: 195
Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J
(1999) Prognostic factors predicting survival from first recurrence in
Survival (months)
18 15 12 9 6 3 0
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Figure 1 The relationship between an inflammation-based prognostic
score (GPS, 0, 1, 2 from top to bottom) and survival in patients with
metastatic breast cancer.
Inflammation-based score in metastatic breast cancer
AM Al Murri et al
229
British Journal of Cancer (2006) 94(2), 227–230 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spatients with metastatic breast cancer: analysis of 439 patients. Breast
Cancer Res Treat 56: 67–78
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer
statistics. CA Cancer J Clin 53: 5–26
Kotler DP (2000) Cachexia. Ann Intern Med 133: 622–634
Kurebayashi J (2000) Regulation of interleukin-6 secretion from breast
cancer cells and its clinical implications. Breast Cancer 7: 124–129
Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage,
treatment, and survival by race and ethnicity. Arch Intern Med 163: 49–56
Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a
prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250–255
Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller
S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S
(2005) Prognostic factors in advanced cancer patients: evidence-based
clinical recommendations–a study by the steering committee of the
European association for palliative care. J Clin Oncol 23: 6240–6248
McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC (2004) The
relationship between circulating concentrations of C-reactive protein,
inflammatory cytokines and cytokine receptors in patients with non-
small-cell lung cancer. Br J Cancer 91: 1993–1995
McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS
(1998) Longitudinal study of body cell mass depletion and the
inflammatory response in cancer patients. Nutr Cancer 31: 101–105
Nomura Y (1998) Different survival determinants of metastatic breast
cancer patients treated with endocrine therapy or chemo-endocrine
therapy. Int J Oncol 12: 817–824
O’Gorman P, McMillan DC, McArdle CS (2000) Factors predicting survival
of advanced gastrointestinal cancer patients with weight loss. Nutr
Cancer 37: 36–40
Sant M (2001) Differences in stage and therapy for breast cancer across
Europe. Int J Cancer 93: 894–901
Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. (2002)
Immune changes in patients with advanced breast cancer undergoing
chemotherapy with taxanes. Br J Cancer 87: 21–27
Williams C, Collingwood M, Simera I, Grafton C (2003) Short versus long
duration infusions of paclitaxel for any adenocarcinoma. Cochrane
Database Syst Rev 1: CD003911
Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumor
progression and prognosis in metastatic breast carcinoma. Anticancer
Res 19: 1427–1432
Inflammation-based score in metastatic breast cancer
AM Al Murri et al
230
British Journal of Cancer (2006) 94(2), 227–230 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s